For help on how to get the results you want, see our search tips.
3 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Referrals Remove Referrals filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Medicine type
Conditional approval Remove Conditional approval filter
Additional monitoring Remove Additional monitoring filter
Referral status
European Commission final decision Remove European Commission final decision filter
Procedure started Remove Procedure started filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Janus kinase inhibitors (JAKi) (updated)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/03/2023 -
List item
Referral: Picato
ingenol mebutate, associated names: Picato, Article 20 procedures
Status: European Commission final decision, opinion/position date: 30/04/2020, EC decision date: 06/07/2020, Last updated: 16/11/2020 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020